Antonio Bertoletti, MD is an expert in the field of viral hepatitis, with a specific interest in the immunopathogenesis of HBV infection. He is a Professor at the Department of Emerging Infectious Diseases at Duke-NUS Medical School, Singapore.  

His current research focuses on the development of new immunological based therapies (TCR-redirected T cells) for the treatment of HBV chronic infection and Hepatocellular carcinoma.     Since COVID-19 pandemic, his laboratory has been actively involved in the characterization of SARS-COV2 specific T cell immune response in infected and vaccinated individuals.